Prednisone News and Research

RSS

New antibody shows promise in active lupus

A new trial involving the use of an antibody called anifrolumab reports improvement in patients with systemic lupus erythematosus (SLE) after 52 weeks of treatment. The research, titled 'Trial of Anifrolumab in Active Systemic Lupus Erythematosus', is published in the New England Journal of Medicine.

19 Dec 2019

Inhaled immunosuppressant could improve prognosis of lung transplant patients

University of Maryland School of Medicine researchers found that lung transplant recipients who had early signs of organ rejection could increase their chances of survival by using an inhaled form of the immunosuppression drug cyclosporine.

13 Nov 2019

Gadolinium-enhanced MRI of shoulders helps predict recurrence of polymyalgia rheumatica

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, use of gadolinium-enhanced magnetic resonance imaging (MRI) in shoulders of patients with polymyalgia rheumatica may contribute to more accurate diagnosis and prediction of recurrence.

11 Nov 2019

UC researcher finds new treatment option for liver transplant patients

A drug commonly used to treat both asthma and inflammatory bowel disease, budesonide, may also be useful as an anti-organ rejection medication for liver transplant patients leading to fewer serious side effects than the most commonly used therapy, according to a University of Cincinnati researcher.

9 Nov 2019

Study identifies several drugs with potential to prevent suicide attempts

A review of 922 prescription medications taken by almost 150 million people over an 11-year period shows that just 10 of these drugs were associated with an increased rate of suicide attempts.

5 Nov 2019

Triple-drug combo inhaler for asthmatics with poor symptom control

New research shows that asthmatics who have poor symptom control could be benefited by using a three-drug combination inhaler. The standard treatment for these patients is a two-drug combination of an inhaled corticosteroid (ICS) and a long acting beta 2 agonist (LABA). The third ingredient added to the mix is a long acting muscarinic antagonist, add the researchers. This combination successfully improved lung function and reduced exacerbations of asthma wrote the researchers.

1 Oct 2019

Deer can pass tuberculosis to humans, CDC warns

Tuberculosis or TB is a highly contagious infection that usually affects the lungs, but it can spread to other parts of the body, such as the spine and brain. Commonly caused by Mycobacterium tuberculosis, which can spread through the air from person to person.

30 Sep 2019

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

An international, multicenter phase II clinical trial is evaluating the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in patients with giant cell arteritis.

26 Sep 2019

Two uveitis drugs perform similarly in a head-to-head clinical trial

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S.

11 Sep 2019

Drug combination could improve survival of lung transplant patients

Lung transplantation can prolong the lives of patients with end-stage lung disease, but the median survival rate after lung transplant is less than six years, which has improved only slightly in recent decades.

28 Aug 2019

Oral steroid use in patients with inflammatory diseases increases risk of infection

Oral steroid use in patients with the inflammatory diseases polymyalgia rheumatica and/or giant cell arteritis significantly increased the risk of infection, and the risk increased with higher doses, found a study in CMAJ.

24 Jun 2019

Study shows high levels of success in most patients despite tapered glucocorticoid discontinuation

The results of a randomized controlled trial presented today at the Annual European Congress of Rheumatology demonstrate high levels of treatment success in approximately two thirds of patients despite tapered glucocorticoid discontinuation, while a small loss of disease control was observed at the total study population level.

13 Jun 2019

New immunosuppressive regimens may improve outcomes for kidney transplant patients

Preliminary results from a $5.2 million clinical trial led by University of Cincinnati researchers show that the immunosuppressive drug belatacept can help safely and effectively treat kidney transplant patients without the negative long-term side effects of traditional immunosuppressive regimens, the study's leaders announced this week.

6 Jun 2019

Study provides new insight into how obesity, insulin resistance can affect cognition

Obesity can break down our protective blood brain barrier resulting in problems with learning and memory, scientists report.

22 Apr 2019

Study findings hold promise for children with DMD

Prednisone, the current standard of care used to treat kids with Duchenne muscular dystrophy (DMD), reduces chronic inflammation but has harsh side effects.

11 Feb 2019

AGA's new clinical guideline to help manage patients with mild-to-moderate ulcerative colitis

Most patients with ulcerative colitis have mild-to-moderate disease characterized by periods of activity or remission, but practice variations exist in disease management.

10 Jan 2019

Potential combination therapy against rare disease of the bone marrow could improve treatment

Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.

19 Dec 2018

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

29 Nov 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended broadening the existing marketing authorization for Darzalex® for use as frontline therapy.

28 Jul 2018